Tapentadol Depot Zentiva 25 mg
Low-dose extended-release opioid analgesic for severe chronic pain
Tapentadol Depot Zentiva 25 mg is a low-strength, extended-release opioid pain medication used for the management of severe chronic pain in adults when non-opioid analgesics are not sufficient. It contains tapentadol as the active ingredient and works through a unique dual mechanism — mu-opioid receptor agonism combined with norepinephrine reuptake inhibition — providing 12-hour sustained pain relief. The 25 mg strength is especially valuable for gradual dose titration, opioid-naive patients, and sensitive populations. This is a prescription-only, controlled-substance medication that requires careful medical supervision due to the risks of addiction, respiratory depression, and life-threatening drug interactions.
Quick Facts
Key Takeaways
- Tapentadol Depot Zentiva 25 mg is a low-dose strong opioid prescribed for severe chronic pain that does not respond to non-opioid analgesics. It should only be used under close medical supervision.
- The 25 mg strength is particularly useful for opioid-naive adults, the elderly, patients with increased sensitivity to opioid side effects, and those requiring fine dose titration or gradual tapering.
- The extended-release tablets must be swallowed whole every 12 hours. Never crush, chew, or break them, as this can cause a life-threatening overdose from rapid drug release.
- Tapentadol has a dual mechanism of action (mu-opioid receptor agonism + norepinephrine reuptake inhibition), which may reduce certain opioid-related side effects compared to pure opioids.
- Do not combine with MAO inhibitors, benzodiazepines, alcohol, or other CNS depressants without medical guidance, as these combinations can be fatal.
What Is Tapentadol Depot Zentiva and What Is It Used For?
Tapentadol Depot Zentiva contains the active substance tapentadol, which belongs to the class of strong opioid analgesics. Unlike traditional opioids such as morphine or oxycodone, tapentadol has a unique dual mechanism of action known as MOR-NRI (mu-opioid receptor agonism combined with norepinephrine reuptake inhibition). This means it works through two complementary pain pathways in the central nervous system simultaneously, producing analgesia through mechanisms that partly overlap with classical opioids and partly with certain antidepressants.
The mu-opioid receptor agonism component modulates pain signals in the brain and spinal cord by activating the same receptors targeted by other opioids, dampening the perception of pain at multiple levels of the nervous system. The norepinephrine reuptake inhibition component enhances the descending pain inhibitory pathways, which are the body's natural pain-suppression system. By engaging both mechanisms simultaneously in a single molecule, tapentadol can provide effective analgesia while potentially causing fewer gastrointestinal side effects (such as constipation and nausea) compared to equipotent doses of traditional pure mu-opioid agonists.
The extended-release (depot) formulation is specifically engineered to release tapentadol gradually over approximately 12 hours, providing steady, round-the-clock pain relief and avoiding the peaks and troughs of plasma drug concentration that can be associated with immediate-release preparations. This pharmacokinetic profile makes it suitable for chronic pain conditions that require continuous, long-term opioid therapy rather than short-term, as-needed use.
The 25 mg strength of Tapentadol Depot Zentiva serves several important clinical purposes. It allows for careful dose initiation in opioid-naive patients, permits gradual upward titration in fine increments when starting treatment, supports cautious use in elderly or debilitated patients who may be more sensitive to opioid effects, and enables gentle dose reduction (tapering) when the time comes to discontinue therapy. Lower-strength tablets play a critical role in reducing the risk of initial over-dosing and giving prescribers the flexibility to individualise therapy carefully.
Tapentadol Depot Zentiva is indicated for:
- Adults with severe chronic pain: Treatment of severe chronic pain in adults that can only be adequately managed with opioid analgesics. This includes chronic musculoskeletal pain, neuropathic pain (such as painful diabetic peripheral neuropathy), and other chronic pain syndromes when lower-potency treatments have failed.
- Patients requiring careful dose titration: The 25 mg strength allows opioid-naive patients to start at the lowest possible dose and gradually increase only if necessary.
- Patients with opioid sensitivity: Individuals who have experienced intolerable side effects from higher-strength opioid tablets may benefit from the lower 25 mg option.
It is important to understand that tapentadol is reserved for patients whose pain is genuinely severe and has not responded adequately to non-opioid treatments such as paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), or adjuvant analgesics. It is not intended for mild or intermittent pain, post-operative pain management (where immediate-release formulations may be more appropriate), or as a first-line analgesic for new-onset pain.
Tapentadol Depot Zentiva is manufactured by Zentiva, a major European pharmaceutical company specialising in generic and off-patent medicines. As a generic product, it must contain the same active ingredient, strength, dosage form, and route of administration as the originator (reference) product, and has been shown to be bioequivalent through regulatory studies. This means patients can expect the same clinical effect as the originator brand, typically at a lower cost to healthcare systems.
What Should You Know Before Taking Tapentadol Depot Zentiva?
Before starting Tapentadol Depot Zentiva, your doctor will review your medical history, current medications, and overall health status to determine whether this medication is appropriate for you. Honest and complete disclosure is essential for your safety.
Contraindications
You must not take Tapentadol Depot Zentiva if any of the following apply to you:
- Allergy to tapentadol or any other ingredient in the tablets. Hypersensitivity reactions can include rash, itching, swelling, or difficulty breathing.
- Severe respiratory depression — if your breathing is dangerously slow or shallow (respiratory depression, hypercapnia). Tapentadol further suppresses the respiratory drive and can cause fatal respiratory arrest in these patients.
- Acute or severe bronchial asthma in an uncontrolled setting, or during asthma attacks, particularly in the absence of monitoring equipment or resuscitative measures.
- Paralytic ileus or known or suspected gastrointestinal obstruction — a condition where the bowel has stopped functioning. Opioids slow gut motility further and can worsen this dangerous condition.
- Acute intoxication with alcohol, sleeping pills, other opioid analgesics, or psychotropic drugs (medications that affect mood and emotions). The combination of CNS depressants with tapentadol can be lethal.
- Concurrent use of MAO inhibitors or use within the last 14 days. The interaction between tapentadol and MAO inhibitors can cause serotonin syndrome, hypertensive crisis, or other life-threatening reactions.
- Conditions where mu-opioid receptor agonists are contraindicated, such as uncompensated hypercapnia.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Tapentadol Depot Zentiva if any of the following conditions apply:
- Respiratory conditions: Slow or shallow breathing, chronic obstructive pulmonary disease (COPD), cor pulmonale, reduced respiratory reserve, hypoxia, hypercapnia, or other conditions that compromise respiratory function. Tapentadol may cause life-threatening respiratory depression, particularly in elderly or debilitated patients. Even the relatively low 25 mg dose should be used with caution in these patients.
- Raised intracranial pressure or impaired consciousness: Including head injury, brain tumors, or reduced level of consciousness. Opioids can obscure the clinical course of patients with head injuries and increase intracranial pressure.
- Liver disease: Patients with moderate hepatic impairment require dose adjustment and close monitoring. Patients with severe hepatic impairment should not take this medication.
- Kidney disease: Patients with severe renal impairment should not take these tablets. No dose adjustment is needed for mild or moderate renal impairment, but the lower 25 mg dose may be useful for cautious initiation.
- Pancreatic or biliary tract disease: Including pancreatitis. Opioids can cause spasm of the sphincter of Oddi, worsening biliary conditions.
- Seizure disorders or epilepsy: Tapentadol may lower the seizure threshold, especially when combined with other medications that increase seizure risk (such as antidepressants or antipsychotics).
- History of substance abuse: If you or a family member has ever misused or been dependent on alcohol, prescription medications, or illegal drugs, you are at increased risk of developing opioid addiction. Inform your doctor honestly about your full history.
- Mental health conditions: Depression, anxiety, personality disorders, or other psychiatric conditions may increase the complexity of opioid management and the risk of misuse. These conditions should be actively treated in parallel.
- Age-related considerations: Elderly patients may be particularly sensitive to the effects of opioids and are more susceptible to respiratory depression, confusion, and falls. The 25 mg strength can be appropriate as a cautious starting dose in this population.
Tapentadol is a controlled substance opioid. Repeated use can lead to tolerance (needing higher doses for the same effect), physical dependence (experiencing withdrawal symptoms if stopped abruptly), and addiction (compulsive drug-seeking behavior). Even use at prescribed therapeutic doses carries risk, and the lower 25 mg strength does not eliminate this risk. If you believe you are developing dependence, contact your doctor immediately. Do not attempt to stop abruptly on your own.
Tapentadol can cause sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low blood oxygen during sleep). Symptoms may include witnessed breathing pauses during sleep, frequent nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime drowsiness. If you or someone observing you notices these symptoms, contact your doctor, who may consider a dose reduction.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Tapentadol Depot Zentiva. The following precautions apply:
- Pregnancy: Do not take Tapentadol Depot Zentiva during pregnancy unless your doctor has specifically instructed you to do so. Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS) in the newborn. NOWS can be life-threatening if not recognized and treated promptly by a physician. Symptoms in the newborn include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremor, vomiting, diarrhea, and failure to gain weight.
- Labor and delivery: Do not use tapentadol during childbirth, as it can cause dangerously slow or shallow breathing (respiratory depression) in the newborn.
- Breastfeeding: Tapentadol may be excreted in breast milk and could affect the nursing infant. Do not breastfeed while taking this medication, as it may cause sedation, respiratory depression, or withdrawal symptoms in the infant when treatment stops.
- Fertility: Long-term opioid use may affect fertility in both men and women. Discuss this with your doctor if you are planning to conceive.
Driving and Operating Machinery
Tapentadol Depot Zentiva can cause drowsiness, dizziness, confusion, and blurred vision, and may impair your reaction time. These effects are most pronounced when starting treatment, during dose changes, or when combined with alcohol or sedative medications. Even the 25 mg dose can produce enough central nervous system effects to make driving hazardous in susceptible individuals.
Do not drive, operate heavy machinery, or perform activities requiring alertness until you know how this medication affects you. Your doctor will advise you on whether it is safe for you to drive, taking into account your overall health, other medications, and the stability of your dose. In many jurisdictions, driving while impaired by prescription opioids is a criminal offence.
How Does Tapentadol Depot Zentiva Interact with Other Drugs?
Drug interactions with tapentadol can be dangerous and, in the case of some combinations, fatal. The dual mechanism of action (opioid agonism and norepinephrine reuptake inhibition) creates interaction potential with a broader range of medications than traditional opioids, because it can affect both the opioid system and the monoamine neurotransmitter systems. It is essential that your doctor and pharmacist know about every medication you take, including herbal products, recreational substances, and medications prescribed by other healthcare providers.
Major Interactions (Potentially Life-Threatening)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| MAO inhibitors (e.g., phenelzine, tranylcypromine, selegiline, moclobemide) | Serotonin syndrome, hypertensive crisis, cardiovascular collapse | Absolutely contraindicated. Do not use within 14 days of MAO inhibitor therapy. |
| Benzodiazepines (e.g., diazepam, lorazepam, alprazolam, clonazepam) | Profound sedation, respiratory depression, coma, death | Avoid combination. If unavoidable, use lowest doses for shortest duration under close monitoring. |
| Other opioids (morphine, codeine, tramadol, oxycodone, fentanyl) | Additive respiratory depression, overdose | Generally avoid concurrent use. Careful dose adjustment if clinically necessary. |
| Alcohol | Enhanced CNS depression, respiratory depression, fatal overdose | Absolutely avoid alcohol during treatment, including alcohol-containing cough syrups and mouthwashes. |
| Serotonergic drugs (SSRIs, SNRIs, triptans, St. John's Wort, tricyclic antidepressants) | Serotonin syndrome — agitation, hyperthermia, myoclonus, autonomic instability | Use with extreme caution. Monitor for serotonin syndrome symptoms. |
| Gabapentinoids (gabapentin, pregabalin) | Increased risk of opioid overdose, respiratory depression, death | Use lowest effective doses. Close monitoring required, particularly at initiation. |
| Sedative hypnotics (zolpidem, zopiclone, eszopiclone) | Additive CNS and respiratory depression | Avoid concurrent use. If necessary, use minimum effective doses with close supervision. |
Moderate Interactions
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| Sedating antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine) | Additive sedation, respiratory depression, anticholinergic effects | Use with caution. Monitor for excessive sedation and confusion. |
| Barbiturates (e.g., phenobarbital, primidone) | Additive CNS depression; phenobarbital may also induce tapentadol metabolism | Avoid if possible. Dose adjustment may be needed. |
| Antipsychotics (e.g., haloperidol, olanzapine, quetiapine) | Additive sedation, lowered seizure threshold, cardiac rhythm disturbances | Monitor closely. Be alert for seizures and orthostatic hypotension. |
| Mixed agonists/antagonists (pentazocine, nalbuphine) or partial agonists (buprenorphine) | Reduced efficacy of tapentadol; potential precipitated withdrawal | Avoid combination. May diminish analgesic effect. |
| Strong enzyme inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort) | Reduced tapentadol efficacy due to accelerated metabolism | Inform your doctor. Dose adjustment may be needed. |
| Muscle relaxants (baclofen, tizanidine, cyclobenzaprine) | Additive CNS depression and sedation | Use with caution. Monitor for excessive drowsiness. |
| Seizure-lowering drugs (bupropion, tramadol, certain antipsychotics) | Increased seizure risk | Use with caution. Monitor for seizure activity. |
When combining tapentadol with serotonergic medications, watch for symptoms of serotonin syndrome: involuntary rhythmic muscle contractions (myoclonus), agitation, excessive sweating, tremor, exaggerated reflexes (hyperreflexia), increased muscle tension, confusion, and body temperature above 38°C (100.4°F). Serotonin syndrome is rare but potentially life-threatening. Seek immediate medical attention if you experience these symptoms.
Always inform your healthcare team about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements such as St. John's Wort. Some combinations that seem harmless can be dangerous when combined with tapentadol. Carry an up-to-date medication list with you to all medical appointments and pharmacy visits, and consider using a single pharmacy so that a pharmacist can screen for interactions.
What Is the Correct Dosage of Tapentadol Depot Zentiva?
Always take Tapentadol Depot Zentiva exactly as your doctor or pharmacist has instructed. The guiding principle of opioid therapy is to use the lowest effective dose for the shortest necessary duration, with regular reviews to assess whether treatment should continue. Your doctor will individualise the dose based on the severity of your pain, your previous analgesic experience, your individual sensitivity to the medication, and the nature of the underlying condition causing your pain.
Adults
Standard Adult Dosing
- Role of the 25 mg strength: Often used as part of a titration scheme, either alongside higher-strength tablets to achieve precise dosing, or as a starting dose in opioid-naive or sensitive patients
- Frequency: Every 12 hours (twice daily), at approximately the same times each day for consistent plasma concentrations
- Dose adjustments: Your doctor may increase or decrease the dose every few days based on your response and tolerability. Do not adjust the dose yourself
- Maximum daily dose: 500 mg of tapentadol in total, divided across two doses 12 hours apart
- If you feel the tablets are too strong or too weak, talk to your doctor — do not adjust the dose yourself
Elderly Patients
Elderly Dosing (over 65 years)
- Routine dose adjustment is generally not necessary in elderly patients with normal organ function
- However, excretion of tapentadol may be delayed in some elderly patients, and the doctor may recommend a lower starting dose and a longer dosing interval
- The 25 mg strength is especially useful as a cautious starting dose in this age group
- Elderly patients are more susceptible to respiratory depression, falls, and confusion, and should be closely monitored, particularly during dose changes
Children and Adolescents
Pediatric Considerations
- The safety and efficacy of extended-release tapentadol has not been established in children under 18 years for most indications in many jurisdictions
- Some tapentadol extended-release products are approved for severe chronic pain in children over 6 years and adolescents, but prescribing varies by country
- If extended-release tapentadol is prescribed to a child or adolescent, it must be done by a specialist experienced in paediatric pain management, with dosing based on age and body weight
- Children and adolescents with liver or kidney problems should generally not take these tablets
- Always follow your prescribing paediatrician's specific instructions
Patients with Organ Impairment
| Condition | Recommendation |
|---|---|
| Mild hepatic impairment | No dose adjustment necessary; standard monitoring applies |
| Moderate hepatic impairment | Lower starting dose and longer dosing interval recommended by your doctor |
| Severe hepatic impairment | Do not use — contraindicated |
| Mild/moderate renal impairment | No dose adjustment necessary; cautious use of the 25 mg dose advised in moderate impairment |
| Severe renal impairment | Do not use — contraindicated |
How to Take the Tablets
Tapentadol Depot Zentiva tablets are taken orally (by mouth). Follow these important instructions precisely:
- Swallow whole with a sufficient amount of liquid (a full glass of water is ideal). Do not crush, chew, break, split, or dissolve the tablets.
- The tablets can be taken with or without food — food does not significantly affect the medication's efficacy or absorption.
- Take the tablets at approximately the same times each day (every 12 hours) for consistent, round-the-clock pain relief.
- The tablet shell may occasionally appear in your stool. This is harmless — the active ingredient has already been absorbed from the controlled-release matrix.
- Do not stop taking the tablets without consulting your doctor. Sudden discontinuation can cause opioid withdrawal symptoms, even after relatively short courses of therapy.
Crushing, chewing, or breaking the extended-release tablet destroys the controlled-release mechanism and can release the entire dose at once. This can cause a fatal overdose, even in patients who are tolerant to opioids. Always swallow the tablet whole. If you cannot swallow tablets, speak to your doctor about alternative formulations.
Missed Dose
If you forget to take a dose, you will likely notice your pain returning. Do not take a double dose to make up for the missed one, as this significantly increases the risk of respiratory depression and other adverse effects. Simply take your next dose at the regular time and continue your usual schedule. If you frequently forget doses, consider using a pill organiser, medication reminder app, or alarm to help establish a routine.
Overdose
If you have taken too much Tapentadol Depot Zentiva, or if a child has accidentally ingested the medication, seek emergency medical help immediately by calling your local poison control centre or emergency services. Accidental paediatric ingestion of even one adult tapentadol tablet can be life-threatening.
Symptoms of overdose may include:
- Pinpoint pupils (miosis)
- Vomiting
- Drop in blood pressure (hypotension)
- Rapid heartbeat (tachycardia), sometimes followed by bradycardia
- Collapse
- Reduced consciousness or coma
- Seizures
- Dangerously slow or shallow breathing, or complete respiratory arrest
- Pulmonary oedema (fluid in the lungs) in severe cases
Respiratory depression is the primary cause of opioid overdose deaths. The opioid antagonist naloxone can reverse respiratory depression caused by tapentadol, but medical supervision is still essential as the effects of naloxone may wear off before the effects of tapentadol, requiring repeated doses or continuous infusion. In many countries, people at risk of opioid overdose (or their family members) can obtain take-home naloxone kits. Ask your prescriber whether this is appropriate for your situation.
Stopping Treatment
Do not stop taking Tapentadol Depot Zentiva suddenly without consulting your doctor. After prolonged use, abrupt discontinuation can cause withdrawal symptoms including:
- Restlessness, watery eyes, runny nose, yawning, sweating, chills, and gooseflesh
- Muscle aches, dilated pupils, irritability, anxiety
- Back pain, joint pain, weakness, abdominal cramps
- Insomnia, nausea, loss of appetite, vomiting, diarrhoea
- Increased blood pressure, increased respiratory rate, increased heart rate
- Craving for the medication
Your doctor will guide you through a gradual dose reduction (tapering) to minimise withdrawal symptoms. The 25 mg strength is particularly valuable during this phase, allowing fine step-down reductions that minimise discomfort. The tapering schedule will be individualised based on your current dose, duration of therapy, and personal response. Rapid or abrupt discontinuation is generally not recommended except in medical emergencies.
What Are the Side Effects of Tapentadol Depot Zentiva?
Like all medicines, Tapentadol Depot Zentiva can cause side effects, although not everybody gets them. The side-effect profile is consistent with the opioid mechanism of action and with norepinephrine reuptake inhibition. Many common side effects improve as your body adjusts to the medication over the first one to two weeks of treatment. Starting with the 25 mg strength and titrating slowly can reduce the severity of these early effects.
Allergic reactions (wheezing, difficulty breathing, swelling of eyelids, face, or lips, widespread rash or itching), breathing that is slower or weaker than expected, severe drowsiness you cannot resist, or signs of serotonin syndrome. Respiratory depression is more common in elderly and debilitated patients. These require emergency medical care.
Very Common
May affect more than 1 in 10 people
- Nausea
- Constipation
- Dizziness
- Drowsiness (somnolence)
- Headache
Common
May affect up to 1 in 10 people
- Decreased appetite
- Anxiety, depressed mood, sleep problems, nervousness, restlessness
- Attention disturbance, tremor, involuntary muscle twitching
- Flushing, shortness of breath
- Vomiting, diarrhoea, digestive discomfort (dyspepsia)
- Itching, increased sweating, skin rash
- Feeling of weakness, fatigue, feeling of altered body temperature
- Dry mucous membranes (especially dry mouth), fluid retention (peripheral oedema)
Uncommon
May affect up to 1 in 100 people
- Allergic reactions (including angioedema, urticaria, severe anaphylaxis)
- Weight loss, disorientation, confusion, agitation
- Perception difficulties, abnormal dreams, euphoria
- Reduced consciousness, memory impairment, mental impairment
- Fainting (syncope), sedation, balance problems, speech difficulties
- Numbness, abnormal skin sensations (tingling, prickling)
- Visual disturbances, increased or decreased heart rate, palpitations
- Decreased blood pressure, abdominal discomfort, urticaria
- Urinary retention, frequent urination, sexual dysfunction
- Drug withdrawal symptoms, feeling abnormal, irritability
Rare
May affect up to 1 in 1,000 people
- Drug dependence
- Abnormal thinking
- Seizures (epileptic fits)
- Pre-syncope (feeling faint), abnormal coordination
- Respiratory depression (dangerously slow or shallow breathing)
- Impaired gastric emptying
- Feeling of intoxication, feeling of relaxation
Delirium has been reported with unknown frequency, particularly in elderly or hospitalised patients. Serotonin syndrome has been observed in association with tapentadol when combined with other serotonergic drugs. Patients with chronic pain may have an increased risk of suicidal thoughts and behaviour; while certain medications that affect neurotransmitters can increase this risk, available clinical data for tapentadol in humans do not show clear evidence of increased suicidal risk. Discuss any worsening mood symptoms promptly with your doctor.
Managing Common Side Effects
Many common side effects can be managed with supportive measures:
- Constipation: Increase fluid and fibre intake, stay physically active where possible, and ask your doctor about a prophylactic laxative (such as macrogol or senna) — constipation from opioids often persists as long as treatment continues.
- Nausea: Usually improves within the first week. Taking the dose with food, avoiding strong odours, and using anti-nausea medications prescribed by your doctor can help.
- Dry mouth: Sip water frequently, chew sugar-free gum, or use saliva substitutes.
- Drowsiness: Avoid driving and operating machinery until effects stabilise. Do not combine with alcohol or sedating medications.
- Dizziness: Rise slowly from sitting or lying positions to reduce the risk of falls, particularly in elderly patients.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. Reporting suspected adverse reactions after marketing authorisation helps with ongoing monitoring of the medicine's benefit-risk balance. Many countries have national yellow-card schemes or web portals for patients and healthcare professionals to report suspected adverse drug reactions.
How Should You Store Tapentadol Depot Zentiva?
Proper storage of opioid medications is critically important for safety, particularly in households with children, adolescents, or individuals at risk of substance misuse. Accidental paediatric ingestion of opioids is a leading cause of preventable poisoning deaths in children, and a single adult tablet can be fatal to a small child. Tapentadol Depot Zentiva tablets are typically supplied in blister packs or containers with child-resistant safety closures. Always ensure the container is fully closed after each use.
- Keep out of the sight and reach of children. Consider a locked medication cabinet, especially if children, teenagers, or visitors with substance-use histories enter your home.
- Do not use after the expiry date stated on the packaging (after "EXP" or similar). The expiry date refers to the last day of that month.
- Follow the specific storage conditions printed on your packaging. Most tapentadol extended-release products do not require refrigeration and can be stored at normal room temperature.
- Protect the tablets from excessive moisture, heat, and direct sunlight. Avoid storage in the bathroom, where humidity can degrade medications over time.
- Disposal: Do not flush unused medications down the toilet or throw them in household waste. Return unused tablets to your pharmacy for safe disposal through pharmaceutical take-back programmes. This protects the environment, prevents accidental exposure, and reduces the risk of diversion or misuse.
If you have leftover medication after completing treatment, dispose of it promptly. Keeping unused opioids in the home increases the risk of accidental ingestion, theft, or diversion. Many pharmacies, hospitals, and local authorities offer take-back programmes for safe medication disposal. Some jurisdictions also offer in-home drug deactivation products (such as activated carbon pouches) that render opioids unusable before disposal.
Beyond the standard pharmacy advice, consider storing opioid medications in a lockbox or safe, especially during family gatherings, periods when contractors or new house guests are present, or when a household member is in recovery from substance-use disorder. Never share your medication with others, even if they have similar symptoms — doing so is illegal in most jurisdictions and can be fatal.
What Does Tapentadol Depot Zentiva Contain?
Active Ingredient
Each extended-release tablet of Tapentadol Depot Zentiva 25 mg contains 25 mg of tapentadol as the active pharmaceutical ingredient, typically in the form of tapentadol maleate hemihydrate or another pharmaceutically acceptable salt. The salt form does not affect the clinical action of the medication, as the tapentadol base is pharmacologically active; the salt form is used to improve stability, solubility, or manufacturing characteristics.
Inactive Ingredients (Excipients)
Excipients in extended-release tapentadol tablets typically include the following categories (exact composition may vary — always refer to the package leaflet for your specific product):
Controlled-release matrix / tablet core: Hypromellose (HPMC — hydroxypropyl methylcellulose) serves as the matrix-forming polymer that regulates the gradual release of tapentadol over 12 hours. Microcrystalline cellulose acts as a compressibility aid and filler. Colloidal anhydrous silicon dioxide is used as a glidant, and magnesium stearate as a lubricant during tablet manufacture.
Film coating: The film coating may contain hypromellose, titanium dioxide (E171) as an opacifier, macrogol (polyethylene glycol) as a plasticiser, and triacetin. Additional colorants such as iron oxides (E172) may be added to differentiate the tablets by strength. The 25 mg tablet often has a distinctive colour to make it easy to distinguish from higher strengths.
Possible sugar content: Some tapentadol extended-release formulations contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to some sugars (such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption), consult your doctor before taking this medicine.
Patients with known allergies to specific dyes or excipients should verify the exact composition of the tablets they receive. Generic medicines may use slightly different excipients from the originator product, though bioequivalence of the active ingredient is assured by regulatory authorities. If you notice any new intolerance after switching between brands of tapentadol, inform your pharmacist.
Tablet Appearance
Tapentadol Depot Zentiva 25 mg extended-release tablets are typically film-coated, oval (oblong) or round in shape, and distinctively coloured to differentiate them from higher strengths. The specific colour, imprint, and dimensions will be described in the package leaflet supplied with your medication.
| Attribute | Description |
|---|---|
| Strength | 25 mg tapentadol (extended-release) |
| Shape | Film-coated oval or round tablet (refer to package leaflet for exact appearance) |
| Imprint | Product-specific marking — see package leaflet |
| Pack sizes | Typically 20, 30, 60, or 100 tablets in blister packs or HDPE containers (availability varies by market) |
| Manufacturer | Zentiva |
If the tablets you receive do not look like those you expect, or if you notice any changes in appearance after a refill, contact your pharmacist before taking the medication. This is an important safety check, especially for opioid medications where accidental substitution could be dangerous.
Frequently Asked Questions
Tapentadol Depot Zentiva is prescribed for the management of severe chronic pain in adults when other non-opioid pain medications have proven insufficient. It is an extended-release formulation that provides approximately 12 hours of continuous pain relief per dose. Common conditions for which it may be prescribed include severe chronic musculoskeletal pain (such as chronic back pain or osteoarthritis pain not controlled by other measures), painful diabetic peripheral neuropathy, and other chronic pain syndromes that require opioid-level analgesia. The 25 mg strength is often used as a starting dose or during careful titration.
The 25 mg dose is the lowest practical starting dose for extended-release tapentadol. It is ideal for opioid-naive patients (those who have not taken opioids before), elderly or frail individuals who are more sensitive to opioid effects, patients with concurrent medical conditions or other medications that increase the risk of side effects, and patients being gradually tapered off opioid therapy. Starting low and going slow is the standard approach in chronic pain management: it reduces the risk of adverse effects, allows your body time to adjust, and helps identify the lowest effective dose for your individual needs.
Tapentadol is unique among opioids because it has a dual mechanism of action: mu-opioid receptor agonism (like traditional opioids) combined with norepinephrine reuptake inhibition (similar to certain antidepressants). This dual mechanism allows tapentadol to provide effective pain relief through two complementary pathways. Clinical studies suggest that this may result in fewer gastrointestinal side effects (especially constipation and nausea) at equivalent analgesic doses compared to pure mu-opioid agonists like morphine or oxycodone. Tapentadol is also considered to have a favourable profile for mixed nociceptive and neuropathic pain.
Tapentadol Depot Zentiva is a generic version of extended-release tapentadol. By law, generic medicines must contain the same active ingredient, in the same amount, in the same dosage form, and for the same route of administration as the originator product. Bioequivalence studies demonstrate that the amount of tapentadol absorbed into the bloodstream, and the rate of absorption, are equivalent to the originator. This means you can expect the same clinical effect. Differences are usually limited to inactive ingredients such as excipients and colourants, tablet shape, and packaging.
The extended-release tablet is designed with a special hydrophilic matrix that slowly releases the medication over 12 hours. If you crush, chew, or break the tablet, you destroy this controlled-release mechanism. The entire 25 mg dose of tapentadol would then be absorbed rapidly rather than over 12 hours, potentially leading to a massive spike in blood concentration. This can cause fatal respiratory depression (your breathing stops) even in individuals who are already tolerant to opioids. Always swallow the tablet whole with liquid. If you have difficulty swallowing tablets, speak to your prescriber about alternative formulations.
No. Alcohol must be completely avoided while taking Tapentadol Depot Zentiva. Alcohol is a central nervous system depressant, and combining it with tapentadol can dramatically increase the risk of life-threatening respiratory depression, profound sedation, coma, and death. Even moderate amounts of alcohol can significantly amplify the dangerous effects of opioids. This includes beer, wine, spirits, and alcohol-containing medications or mouthwashes. Additionally, alcohol can theoretically disrupt the controlled-release mechanism of some extended-release formulations.
If you suspect an overdose, call your local emergency services or poison control centre immediately. Symptoms of overdose include pinpoint pupils, vomiting, low blood pressure, rapid heartbeat, loss of consciousness, seizures, and dangerously slow or absent breathing. While waiting for emergency help, try to keep the person awake, talking, and breathing. Place them in the recovery position if they are unconscious but breathing. If available, naloxone (an opioid-reversal agent) can be administered intranasally or by injection. Even after naloxone, emergency medical care is still essential, because naloxone wears off faster than tapentadol.
No, you should not stop taking tapentadol abruptly after prolonged use, as this can trigger opioid withdrawal symptoms including restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle aches, anxiety, insomnia, nausea, vomiting, and diarrhoea. The 25 mg strength is especially useful during the tapering process, allowing gradual, well-tolerated dose reductions. Your doctor will create a tapering plan tailored to your specific situation — typically involving small reductions every one to four weeks. Always discuss any desire to stop treatment with your doctor first, and never attempt to taper faster than recommended.
References
This article is based on the following evidence-based sources:
- European Medicines Agency (EMA). Tapentadol — Summary of Product Characteristics (SmPC). Available at: ema.europa.eu.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents (2018). Geneva: WHO.
- Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. “Is tapentadol different from classical opioids? A review of the evidence.” British Journal of Pain. 2016;10(4):217–221.
- Tzschentke TM, et al. “Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.” Drugs of Today. 2009;45(7):483–496.
- National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE guideline [NG193]. 2021.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- Kress HG. “Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally acting analgesics on the horizon?” European Journal of Pain. 2010;14(8):781–783.
- British National Formulary (BNF). Tapentadol monograph. Available at: bnf.nice.org.uk.
- Schwittay A, Schumann C, Litzenburger BC, Schwenke K. “Tapentadol prolonged release for severe chronic pain: observational study in clinical practice.” Pain Management. 2013;3(4):251–262.
- European Pain Federation (EFIC). Opioid Prescribing Guidance for Chronic Pain. Available at: europeanpainfederation.eu.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in pain medicine, clinical pharmacology, and evidence-based medicine.
iMedic Medical Editorial Team — specialists in pharmacology and pain medicine with clinical and academic expertise.
iMedic Medical Review Board — independent panel of board-certified physicians reviewing all content against international guidelines (EMA, WHO, FDA, NICE, BNF).
Editorial Standards: All medication information follows the GRADE evidence framework and is cross-referenced with the European Medicines Agency SmPC, WHO guidelines, and current peer-reviewed literature. No commercial funding or pharmaceutical sponsorship influences our content. Read more about our editorial standards.